Physician profile
Daniel Shibuya
NPI 1275639304
$13,454.46
in general payments reported to CMS, 2019-2025
47 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $430 · 2021: $220 · 2022: $2,157 · 2023: $2,820 · 2024: $2,639 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,461 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,461.12 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,859.88 | 2019-2025 | Qulipta, Botox, Ubrelvy |
| Emd Serono, INC. | $1,315.88 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $984.57 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $920.12 | 2019-2025 | Nuplazid |
| Biogen, INC. | $864.51 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $769.76 | 2019-2025 | Rystiggo, Nayzilam, Fintepla |
| Alexion Pharmaceuticals, INC. | $752.87 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $529.68 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $516.46 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $463.05 | 2019-2025 | Uplizna |
| Csl Behring | $449.15 | 2021-2025 | Hizentra, Privigen |
| Lilly USA, LLC | $358.34 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Neurocrine Biosciences, INC. | $354.28 | 2019-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $314.60 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $232.42 | 2019-2023 | Inbrija |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $231.37 | 2020-2025 | Vyepti |
| Pfizer INC. | $225.05 | 2019-2025 | |
| Eisai INC. | $217.17 | 2022-2025 | |
| Genzyme Corporation | $213.73 | 2019-2025 | |
| Celgene Corporation | $203.99 | 2022-2025 | Zeposia |
| Sk Life Science, INC. | $183.73 | 2021-2025 | |
| Neurelis, INC. | $152.96 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $137.85 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $136.10 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $128.87 | 2022-2023 | |
| Greenwich Biosciences, INC. | $118.39 | 2019 | |
| Trilliant Surgical LLC. | $89.67 | 2023 | Arsenal Ankle 10 Hole 1/3 Tubular Plate |
| Alnylam Pharmaceuticals INC. | $74.02 | 2022-2024 | Amvuttra |
| Ge Healthcare | $67.51 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.28 | 2024-2025 | Rexulti |
| Impel Pharmaceuticals INC. | $52.41 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $49.33 | 2025 | |
| Abbott Laboratories | $46.96 | 2022-2023 | Infinity |
| Amneal Pharmaceuticals LLC | $46.51 | 2022-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Impel Pharmaceuticals LLC | $40.13 | 2025 | Trudhesa |
| Vertex Pharmaceuticals Incorporated | $30.97 | 2025 | |
| Banner Life Sciences, LLC | $30.30 | 2024 | |
| Tanabe Pharma America, INC. | $28.93 | 2019-2022 | |
| Allergan, INC. | $28.63 | 2019 | |
| Horizon Therapeutics Plc | $28.20 | 2022 | |
| Grifols USA, LLC | $27.29 | 2024 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $24.16 | 2024 | Dysport |
| Catalyst Pharmaceuticals, INC. | $22.94 | 2025 | |
| Kyowa Kirin, INC. | $22.91 | 2024 | Nourianz |
| Sanofi-Aventis U.S. LLC | $20.64 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.68 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.21 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shibuya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.